Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 2 |
2021 | 1 |
2022 | 3 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
J Neurooncol. 2022 Sep;159(3):509-518. doi: 10.1007/s11060-022-04088-3. Epub 2022 Jul 17.
J Neurooncol. 2022.
PMID: 35842871
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Hagiwara A, Oughourlian TC, Cho NS, Schlossman J, Wang C, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Rodriguez FJ, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Prins RM, Cloughesy TF, Ellingson BM.
Hagiwara A, et al. Among authors: schlossman j.
Neuro Oncol. 2022 Jun 1;24(6):1020-1028. doi: 10.1093/neuonc/noab276.
Neuro Oncol. 2022.
PMID: 34865129
Free PMC article.
Item in Clipboard
Head-to-head comparison of commercial artificial intelligence solutions for detection of large vessel occlusion at a comprehensive stroke center.
Schlossman J, Ro D, Salehi S, Chow D, Yu W, Chang PD, Soun JE.
Schlossman J, et al.
Front Neurol. 2022 Oct 10;13:1026609. doi: 10.3389/fneur.2022.1026609. eCollection 2022.
Front Neurol. 2022.
PMID: 36299266
Free PMC article.
Item in Clipboard
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF.
Ellingson BM, et al. Among authors: schlossman j.
Neurooncol Adv. 2021 Jun 19;3(1):vdab082. doi: 10.1093/noajnl/vdab082. eCollection 2021 Jan-Dec.
Neurooncol Adv. 2021.
PMID: 34377989
Free PMC article.
Item in Clipboard
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM.
Patel KS, et al. Among authors: schlossman j.
Neurosurgery. 2020 Oct 15;87(5):931-938. doi: 10.1093/neuros/nyaa135.
Neurosurgery. 2020.
PMID: 32365185
Free PMC article.
Item in Clipboard
Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.
Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM.
Oughourlian TC, et al. Among authors: schlossman j.
J Neurooncol. 2020 Mar;147(1):135-145. doi: 10.1007/s11060-020-03407-w. Epub 2020 Jan 24.
J Neurooncol. 2020.
PMID: 31981013
Free PMC article.
Item in Clipboard
pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM.
Yao J, et al. Among authors: schlossman j.
J Neurooncol. 2019 May;142(3):587-595. doi: 10.1007/s11060-019-03132-z. Epub 2019 Feb 26.
J Neurooncol. 2019.
PMID: 30806888
Free PMC article.
Item in Clipboard
Cite
Cite